PDCD1 and nasopharyngeal carcinoma: Our group is conducting a phase 3 trial testing the efficacy of cadonilimab, a bi-specific antibody targeting PD-1/CTLA-4, in locoregionally advanced NPC, which may provide further evidence for this strategy (NCT05587374).